Product Description
BMX (Bone Marrow Kinase on the X chromosome), also known as ETK, is a member of the non-receptor tyrosine kinase family belonging to the Tec kinase subfamily, which plays a pivotal role in cell survival, proliferation, differentiation, and cytoskeletal reorganization. BMX is activated downstream of integrins, cytokine receptors, and G-protein-coupled receptors, leading to phosphorylation of downstream effectors such as AKT, STAT3, and MAPKs. Beyond its essential physiological functions in hematopoiesis and immune responses, dysregulation of BMX signaling—including overexpression and aberrant activation—is closely associated with various cancers (such as prostate, breast, and leukemia), inflammatory diseases, and angiogenesis, making it a highly validated target for cancer therapy and drug discovery.
Screeningbio’s BMX Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying BMX kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: BMX catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the BMX kinase.
Data